Breaking down barriers to identify hemorrhagic transformation in ischemic stroke

Neurology

Volumn 79, Issue 16, 2012, Pages 1632-1633

  Jickling, Glen C ^a,b   Manolescu, Bogdan N ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY POLITEHNICA OF BUCHAREST   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CLAUDIN 5; COLLAGEN TYPE 4; FIBRINOLYTIC AGENT; GELATINASE B; GLUCOSE; MINOCYCLINE; NEURON SPECIFIC ENOLASE; OCCLUDIN; PROTEIN S100B; PROTEIN ZO1; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN;

ANTICOAGULANT THERAPY; BLOOD BRAIN BARRIER; BLOOD SAMPLING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; DIET RESTRICTION; DRUG INHIBITION; EDITORIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HEMORRHAGIC TRANSFORMATION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; MORBIDITY; MORTALITY; NEUROIMAGING; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; RISK FACTOR; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SYMPTOM;

EID: 84871251089     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31826e9b9d     Document Type: Editorial

References (13)

1. Kazmierski R, Michalak S, Wencel-Warot A, Nowinski WL. Serum tight-junction proteins predict hemorrhagic transformation in ischemic stroke patients. Neurology 2012;79:1677-1685.
2. Bang OY, Buck BH, Saver JL, et al. Prediction of hemorrhagic transformation after recanalization therapy using T2*-permeability magnetic resonance imaging. Ann Neurol 2007;62:170-176.
3. Kassner A, Roberts T, Taylor K, Silver F, Mikulis D. Prediction of hemorrhage in acute ischemic stroke using permeability MR imaging. AJNR Am J Neuroradiol 2005;26: 2213-2217.
4. Montaner J, Molina CA, Monasterio J, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603.
5. Castellanos M, Leira R, Serena J, et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003;34: 40-46.
6. Rosell A, Cuadrado E, Ortega-Aznar A, Hernandez-Guillamon M, Lo EH, Montaner J. MMP-9-positive neutrophil infiltration is associated to blood-brain barrier breakdown and basal lamina type IV collagen degradation during hemorrhagic transformation after human ischemic stroke. Stroke 2008;39:1121-1126.
7. Castellanos M, Leira R, Serena J, et al. Plasma cellularfibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004;35:1671-1676.
8. Ribo M, Montaner J, Molina CA, et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004;35:2123-2127.
9. Foerch C, Wunderlich MT, Dvorak F, et al. Elevated serum S100B levels indicate a higher risk of hemorrhagic transformation after thrombolytic therapy in acute stroke. Stroke 2007;38:2491-2495.
10. Abumiya T, Yokota C, Kuge Y, Minematsu K. Aggravation of hemorrhagic transformation by early intraarterial infusion of low-dose vascular endothelial growth factor after transient focal cerebral ischemia in rats. Brain Res 2005;1049:95-103.
11. Murata Y, Rosell A, Scannevin RH, Rhodes KJ, Wang X, Lo EH. Extension of the thrombolytic time window with minocycline in experimental stroke. Stroke 2008;39: 3372-3377.
12. Switzer JA, Hess DC, Ergul A, et al. Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke 2011;42: 2633-2635.
13. Dzialowski I, Pexman JH, Barber PA, Demchuk AM, Buchan AM, Hill MD. Asymptomatic hemorrhage after thrombolysis may not be benign: prognosis by hemorrhage type in the Canadian alteplase for stroke effectiveness study registry. Stroke 2007;38:75-79.